Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.

Vitucci M, Karpinich NO, Bash RE, Werneke AM, Schmid RS, White KK, McNeill RS, Huff B, Wang S, Van Dyke T, Miller CR.

Neuro Oncol. 2013 Oct;15(10):1317-29. doi: 10.1093/neuonc/not084. Epub 2013 Jun 27.

2.

A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.

El Meskini R, Iacovelli AJ, Kulaga A, Gumprecht M, Martin PL, Baran M, Householder DB, Van Dyke T, Weaver Ohler Z.

Dis Model Mech. 2015 Jan;8(1):45-56. doi: 10.1242/dmm.018168. Epub 2014 Nov 27.

3.

Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.

Schmid RS, Simon JM, Vitucci M, McNeill RS, Bash RE, Werneke AM, Huey L, White KK, Ewend MG, Wu J, Miller CR.

Neuro Oncol. 2016 Jul;18(7):962-73. doi: 10.1093/neuonc/nov321. Epub 2016 Jan 28.

4.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7.

5.

A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma.

Read RD, Fenton TR, Gomez GG, Wykosky J, Vandenberg SR, Babic I, Iwanami A, Yang H, Cavenee WK, Mischel PS, Furnari FB, Thomas JB.

PLoS Genet. 2013;9(2):e1003253. doi: 10.1371/journal.pgen.1003253. Epub 2013 Feb 14.

6.

Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

Acquaviva J, Jun HJ, Lessard J, Ruiz R, Zhu H, Donovan M, Woolfenden S, Boskovitz A, Raval A, Bronson RT, Pfannl R, Whittaker CA, Housman DE, Charest A.

Cancer Res. 2011 Dec 1;71(23):7198-206. doi: 10.1158/0008-5472.CAN-11-1514. Epub 2011 Oct 10.

7.

Invasive glioblastoma cells acquire stemness and increased Akt activation.

Molina JR, Hayashi Y, Stephens C, Georgescu MM.

Neoplasia. 2010 Jun;12(6):453-63.

8.

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.

Koul D, Wang S, Wu S, Saito N, Zheng S, Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, Shiose Y, Sulman EP, Hirota Y, Yung WKA.

Oncotarget. 2017 Mar 28;8(13):21741-21753. doi: 10.18632/oncotarget.15566.

9.

Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.

de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, Depinho RA, Bonni A.

Genes Dev. 2008 Feb 15;22(4):449-62. doi: 10.1101/gad.1606508. Epub 2008 Feb 7.

10.
11.

PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.

Thomas SL, Alam R, Lemke N, Schultz LR, Gutiérrez JA, Rempel SA.

Neuro Oncol. 2010 Sep;12(9):941-55. doi: 10.1093/neuonc/noq048. Epub 2010 May 14.

12.
13.

Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.

Onken J, Torka R, Korsing S, Radke J, Krementeskaia I, Nieminen M, Bai X, Ullrich A, Heppner F, Vajkoczy P.

Oncotarget. 2016 Mar 1;7(9):9876-89. doi: 10.18632/oncotarget.7130.

14.

mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.

Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC.

Neoplasia. 2005 Apr;7(4):356-68.

15.

MicroRNA-377 inhibited proliferation and invasion of human glioblastoma cells by directly targeting specificity protein 1.

Zhang R, Luo H, Wang S, Chen W, Chen Z, Wang HW, Chen Y, Yang J, Zhang X, Wu W, Zhang SY, Shen S, Dong Q, Zhang Y, Jiang T, Lu D, Zhao S, You Y, Liu N, Wang H.

Neuro Oncol. 2014 Nov;16(11):1510-22. doi: 10.1093/neuonc/nou111. Epub 2014 Jun 20.

16.

Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.

Doll S, Urisman A, Oses-Prieto JA, Arnott D, Burlingame AL.

Mol Cell Proteomics. 2017 Jan;16(1):39-56. doi: 10.1074/mcp.M116.063883. Epub 2016 Nov 10.

17.

Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ.

Cancer Res. 2009 Mar 15;69(6):2540-9. doi: 10.1158/0008-5472.CAN-08-1547. Epub 2009 Mar 10.

18.

Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes.

Senger DL, Tudan C, Guiot MC, Mazzoni IE, Molenkamp G, LeBlanc R, Antel J, Olivier A, Snipes GJ, Kaplan DR.

Cancer Res. 2002 Apr 1;62(7):2131-40.

19.

Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation.

Molina JR, Morales FC, Hayashi Y, Aldape KD, Georgescu MM.

Cancer Res. 2010 Sep 1;70(17):6697-703. doi: 10.1158/0008-5472.CAN-10-1271. Epub 2010 Aug 24.

20.

An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9.

Zhao Y, Xiao A, diPierro CG, Carpenter JE, Abdel-Fattah R, Redpath GT, Lopes MB, Hussaini IM.

Am J Pathol. 2010 Jun;176(6):3032-49. doi: 10.2353/ajpath.2010.090571. Epub 2010 Apr 22.

Supplemental Content

Support Center